Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

ABSTRACT:

Background/aims

Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affecting PFS of crizotinib and develop a prognostic model for advanced ALK-positive NSCLC.

Methods

Clinicopathologic features of patients enrolled in PROFILE 1001, 1005, 1007, and 1014 (training cohort) were reviewed. We conducted multivariate Cox analysis for PFS and overall survival (OS) in the training cohort (n = 159) and generated a proportional hazards model based on significant clinicopathologic factors, and then validated the model in an independent validation cohort (n = 40).<

SUBMITTER: Ock CY 

PROVIDER: S-EPMC6718771 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature